Frazier Life Sciences Management L.P. Makes New $15.10 Million Investment in Dyne Therapeutics, Inc. $DYN

Key Points

• Frazier Life Sciences Management L.P. acquired 1,443,341 shares of Dyne Therapeutics, valued at approximately $15.1 million, representing 1.27% ownership according to their latest SEC filing.
• Dyne Therapeutics reported a quarterly earnings per share (EPS) of ($0.97), slightly beating expectations of ($0.99), and analysts project a -3.44 EPS for the current fiscal year.
• Current institutional investors own 96.68% of Dyne Therapeutics stock, while insider ownership stands at 20.77%, with CEO John Cox increasing his shareholding significantly.

Frazier Life Sciences Management L.P. acquired a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,443,341 shares of the company's stock, valued at approximately $15,097,000. Frazier Life Sciences Management L.P. owned approximately 1.27% of Dyne Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Braidwell LP lifted its holdings in shares of Dyne Therapeutics by 431.6% in the first quarter. Braidwell LP now owns 3,621,344 shares of the company's stock worth $37,879,000 after acquiring an additional 2,940,162 shares during the last quarter. Armistice Capital LLC lifted its holdings in shares of Dyne Therapeutics by 187.0% in the first quarter. Armistice Capital LLC now owns 2,768,000 shares of the company's stock worth $28,953,000 after acquiring an additional 1,803,482 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $42,408,000. Siren L.L.C. lifted its holdings in shares of Dyne Therapeutics by 101.7% in the first quarter. Siren L.L.C. now owns 2,717,987 shares of the company's stock worth $28,430,000 after acquiring an additional 1,370,531 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in shares of Dyne Therapeutics in the first quarter worth about $12,218,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Trading Down 1.8%

NASDAQ DYN traded down $0.24 during trading hours on Thursday, reaching $13.24. The company's stock had a trading volume of 1,751,830 shares, compared to its average volume of 2,419,008. The firm has a fifty day simple moving average of $10.70 and a 200-day simple moving average of $11.16. The stock has a market cap of $1.88 billion, a P/E ratio of -3.43 and a beta of 1.10. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $37.08. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. Equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other news, CEO John Cox purchased 100,000 shares of the stock in a transaction on Monday, July 14th. The stock was purchased at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the acquisition, the chief executive officer owned 242,179 shares in the company, valued at $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 14.14% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

DYN has been the subject of a number of research reports. Guggenheim reissued a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, June 18th. Raymond James Financial raised shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $31.00 to $35.00 in a report on Monday, August 25th. Robert W. Baird dropped their target price on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a report on Wednesday, June 18th. Jones Trading assumed coverage on shares of Dyne Therapeutics in a report on Thursday, June 26th. They issued a "buy" rating and a $30.00 target price for the company. Finally, HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Dyne Therapeutics presently has an average rating of "Buy" and an average target price of $34.07.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.